Nacif v. Athira Pharma Inc

District Court, W.D. Washington·Decided September 27, 2023·No. 2:21-cv-00861·Unknown

Opinion

1 2

3 4 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON 5 AT SEATTLE 6 ANTONIO BACHAALANI NACIF and WIES RAFI, individually and on behalf 7 of all others similarly situated, 8 Plaintiffs, C21-0861 TSZ 9 v. ORDER 10 ATHIRA PHARMA, INC.; and LEEN KAWAS, Ph.D., 11 Defendants. 12

13 THIS MATTER comes before the Court on plaintiffs’ unopposed motion for 14 preliminary approval of a proposed class settlement, docket no. 118. By Minute Order 15 entered May 31, 2023, docket no. 119, the Court directed counsel to meet and confer and 16 to file a Joint Status Report addressing several issues. Having reviewed the Joint Status 17 Report (“JSR”), docket no. 122, and other materials submitted by the parties, the Court 18 enters the following Order. 19 Background 20 This case involves publicly traded common stock of defendant Athira Pharma, Inc. 21 (“Athira”), some of which was acquired in connection with Athira’s initial public 22 offering (“IPO”) in September 2020, some of which was purchased when Athira 1 conducted a secondary public offering (“SPO”) in January 2021, and some of which 2 cannot be traced to either the IPO or the SPO. In this litigation, claims have been made

3 pursuant to: 4 (i) Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (“Exchange Act”), 15 U.S.C. §§ 78j(b) & 78t(a), and United States 5 Securities and Exchange Commission (“SEC”) Rule 10b-5, 17 C.F.R. § 240.10b-5 (collectively, the “Exchange Act Claims”); and 6 (ii) Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 7 (“Securities Act”), 15 U.S.C. §§ 77k, 77l, and 77o (collectively, the “Securities Act Claims”). 8 Among the individuals who sought appointment as lead plaintiff in this action, Antonio 9 Bachaalani Nacif had the largest financial interest1 and Wies Rafi had the next largest 10 financial interest.2 See Order at 5 (docket no. 60). Because Nacif, however, cannot trace 11 his stock purchases to the IPO or the SPO and therefore has no standing to assert any 12 claim under the Securities Act, the Court also appointed Rafi as a co-lead plaintiff. See 13 id. at 5–9. On January 7, 2022, after their appointment as co-lead plaintiffs, Nacif and 14 Rafi filed the operative pleading, captioned as the Consolidated Amended Complaint 15 (“CAC”), docket no. 74. See Order at 1 n.1 (docket no. 89). 16 By Order entered July 29, 2022, docket no. 89 (“Dismissal Order”), the Court 17 granted in part and denied in part a motion to dismiss brought by defendants, namely 18 19 1 From February 19, 2021, until June 16, 2021, Nacif engaged in active trading of Athira stock, purchasing or selling shares multiple times each week. See Exs. A & B to Townsend Decl. 20 (docket nos. 41-1 & 41-2). As of June 17, 2021, Nacif held 49,007 shares in two accounts. Id. 2 Rafi purchased 150 shares on October 20, 2020, and another 6,450 shares on November 16, 21 2020. Exs. B & C to Nivison Decl. (docket no. 43-2 & 43-3). All of these shares were sold on June 18, 2021, at a loss, which Rafi’s counsel has quantified differently under the Securities Act 22 ($44,737.92) and the Exchange Act ($94,145.10). Id. at Ex. C (docket no. 43-3). 1 Athira, Athira’s founder and former Chief Executive Officer (Leen Kawas, Ph.D.), 2 Athira’s Chief Financial Officer, members of Athira’s Board of Directors, and the

3 underwriters for Athira’s stock offerings. See Dismissal Order (docket no. 89). 4 Plaintiffs’ Exchange Act Claims were dismissed, without prejudice and with leave to 5 amend as to Athira and the individual defendants, but with prejudice as to the 6 underwriters.3 See id. at 29–32, 38–39, & 43–49. Except as to claims against Athira and 7 Kawas with respect to a registration statement designated as “Statement 3,”4 plaintiffs’ 8 Securities Act Claims were also dismissed, but with leave to amend the claims asserted

9 3 The underwriters (Goldman Sachs & Co. LLC, Jeffries LLC, JMP Securities LLC, and Stifel 10 Nicolaus & Company, Inc.) filed a motion for entry of judgment pursuant to Federal Rule of Civil Procedure 54(b), which the Court deferred pending further briefing on the proposed form 11 of partial judgment set forth in the Order entered February 17, 2023, docket no. 114. Pursuant to the parties’ stipulation, docket no. 117, the underwriters’ Rule 54(b) motion was stricken without 12 prejudice to refiling in the event that a settlement of this matter is not perfected. Docket Entry (Mar. 10, 2023). 13 4 Statement 3, which appeared in each prospectus, indicated that, “[i]n December 2011, we entered into an exclusive license agreement with Washington State University Research Fund, or 14 WSURF, which, after the dissolution of WSURF in 2013, was superseded by an amended and restated exclusive license agreement with Washington State University, or WSU, in September 15 of 2015. Under this agreement, WSU granted us an exclusive license to make, use, sell, and offer for sale licensed products and licensed processes that embody the licensed patents (including 16 WSU’s rights to a patent jointly owned with Pacific Northwest Biotechnology, Inc.) and that form the underlying technology of the drug therapies we are developing.” CAC at ¶¶ 113, 178, 17 & 181 (docket no. 74). In denying defendants’ motion to dismiss the Sections 11 and 15 claims against Athira and Kawas as to Statement 3, the Court concluded that “plaintiffs have pleaded a 18 plausible claim that the failure to disclose Kawas’s mistakes as a graduate student, while touting the exclusivity of a license for patents founded on Kawas’s doctoral work, might have ‘misled a reasonable investor about the nature of his or her investment.’” Dismissal Order at 43 (docket 19 no. 89) (quoting In re Daou Sys., Inc., Sec. Litig., 411 F.3d 1006, 1027 (9th Cir. 2005)). In subsequently denying defendants’ motion for reconsideration of this ruling, the Court reasoned 20 that it could not, “based solely on the operative pleading,” draw the conclusion that “the omitted fact (namely, Kawas’s alteration of certain images in her dissertation and research papers) is ‘so 21 obviously unimportant that no reasonable shareholder could have viewed it as significantly altering the ‘total mix’ of information made available to stockholders.’” Minute Order at ¶ 1 22 (docket no. 95) (quoting Hemmer Grp. v. SW. Water Co., 527 F. App’x 623, 626 (9th Cir. 2013)). 1 under Sections 11 and 15 of the Securities Act.5 Id. at 36–43. Plaintiffs did not, 2 however, amend their pleading by the deadline of August 19, 2022, and no additional

3 party was joined (or rejoined) by the deadline of December 16, 2022. See id. at 50; 4 Minute Order at 1 (docket no. 100); see also Order at 5 (docket no. 114) (“The Court is 5 satisfied that plaintiffs’ decision not to timely amend their operative pleading renders 6 ‘final’ the earlier dismissal without prejudice.” (citing Hunt v Bloom Energy Corp., 7 No. 19-cv-2935, 2021 WL 6617453, at *2 (N.D. Cal. Dec. 1, 2021))). 8 Plaintiffs now seek certification for settlement purposes of a class that includes

Free access — add to your briefcase to read the full text and ask questions with AI

Nacif v. Athira Pharma Inc, (W.D. Wash. 2023).

Nacif v. Athira Pharma Inc (Nacif v. Athira Pharma Inc) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related